NL-OMON37479已完成不适用
A SINGLE-CENTER, OPEN-LABEL, ONE-SEQUENCE, THREE-PERIOD CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF HP-3040 PATCHES (TOLTERODINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 168-HR APPLICATION COMPARED TO SINGLE-DOSE DETROL® LA 2 MG (TOLTERODINE TARTRATE EXTENDED RELEASE CAPSULE) IN HEALTHY ADULT MALE SUBJECTS - HP-3040 transdermal patch study
oven Pharmaceuticals, Inc0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •18-45 yrs, inclusive
- •BMI: 18.0-30.0 kg/m2, inclusive
- •non-smoking or a light smoker (less than 5 cigarettes per day for minimal 6 months)
- •light skin color
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, THREE-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THE HP-3070 PATCH (ASENAPINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO SINGLE-DOSE SYCREST® 5 MG (ASENAPINE, SUBLINGUAL) IN HEALTHY ADULT MALE AND FEMALE SUBJECTSbipolar disorder10026753SchizophreniaNL-OMON36902oven Pharmaceuticals, Inc.18
已完成
1 期
Phase 1 study of DS-8201a in subject with Advanced Solid Malignant TumorsJPRN-jRCT2080223734DAIICHI SANKYO CO., LTD.32
已完成
不适用
A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, 3-WAY CROSSOVER STUDY TO COMPARE THE RATE AND EXTENT OF RIVASTIGMINE ABSORPTION FROM A 7 DAY RIVASTIGMINE TRANSDERMAL SYSTEM (7-DAY RTS) WITH AND WITHOUT OVERLAY WITH 24-HR EXELON® PATCH APPLIED DAILY FOR 7 DAYS IN HEALTHY MALE AND FEMALE SUBJECTS10012272dementiaNL-OMON38506oven Pharmaceuticals, Inc.18
进行中（未招募）
1 期
A phase III study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in adults vaccinated against COVID-19SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2022-000074-25-ITHIPRA SCIENTIFIC S.L.3,000
进行中（未招募）
1 期
A study to evaluate the safety, tolerability, processing by the body and mechanism of action of multiple doses of ralmitaront with a single dose of risperidone administered to healthy participantsSafety, tolerability, pharmacokinetics and pharmacodynamics of ralmitaront and risperidone in healthy participantsISRCTN14984258Roche (Switzerland)20